معرفی
Kim Theilgaard-Mønch is an Associate Professor and Clinical Associate Professor at the Department of Clinical Medicine, University of Copenhagen. He serves as Group Leader of Theilgaard Group at the Finsen Laboratory, Rigshospitalet, and holds a combined clinical and research position as Senior Consultant in the Department of Hematology at Rigshospitalet. His work spans the Biotech Research and Innovation Centre, Program for Translational Hematology, DanStem, and the NNF Center for Stem Cell Research at the University of Copenhagen.
Dr. Theilgaard-Mønch received his medical education from the University of Heidelberg in 1992, followed by an ECFMG certificate in 1994. He earned his DMSc from Rigshospitalet and the University of Copenhagen in 2007, and became board certified as a specialist in Internal Medicine & Hematology in 2017.
His primary research focuses on Acute Myeloid Leukemia (AML) and hematopoietic stem cells, with particular emphasis on leukemic stem cells and clinical trials. His current research involves identifying and therapeutically targeting oncogenic signaling and DNA damage response pathways in preclinical AML models, developing novel antibody-drug conjugate therapies targeting leukemic stem cells, and applying human hematopoietic stem cell markers for refining HSC phenotypes and producing purified stem cell grafts. He is particularly interested in normal and malignant hematopoietic/myeloid development.
Analysis of Dr. Theilgaard-Mønch's extensive publication record (70 research outputs) reveals a strong focus on translational hematology and AML research. His work spans molecular mechanisms of AML pathogenesis, therapeutic targeting strategies, stem cell biology, and clinical trial design. Key themes include DNA damage response pathways, signaling inhibition, stem cell markers, and treatment optimization for AML patients, with significant contributions to understanding venetoclax resistance mechanisms and novel therapeutic approaches.
Dr. Theilgaard-Mønch serves as the sponsoring Principal Investigator for a translational exploratory investigator-initiated AML trial conducted in collaboration with 14 Nordic AML centers. This trial performs comprehensive AML profiling including genomics, transcriptomics, phosphoproteomics, and ex vivo drug screening to identify novel drug combinations targeting therapy-resistant minimal residual disease and leukemic stem cells. His research has been supported by a Novo Nordisk clinical research scholarship from 2013-2017.
He leads Theilgaard Group, which is part of the Finsen Laboratory at Rigshospitalet and the Biotech Research and Innovation Centre at the University of Copenhagen. The group maintains strong collaborations with the Nordic AML Group and has established research networks across multiple institutions, with significant external collaboration at the country/territory level. His work bridges basic science and clinical application, with emphasis on translating laboratory findings into improved patient outcomes for AML.
